Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
Seonggyu Byeon, Youjin Kim, Sung Won Lim, Jang Ho Cho, Sehoon Park, Jiyun Lee, Jong-Mu Sun, Yoon-La Choi, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2019;51(2):623-631.   Published online 2018 Jul 23     DOI: https://doi.org/10.4143/crt.2018.151
Citations to this article as recorded by Crossref logo
Advances in the Diagnosis and Treatment of Advanced Non–Small-Cell Lung Cancer With EGFR Exon 20 Insertion Mutation
Jingwen Liu, Yan Xiang, Tingwen Fang, Lulin Zeng, Ao Sun, Yixiang Lin, Kaihua Lu
Clinical Lung Cancer.2024; 25(2): 100.     CrossRef
Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability
Maximilian J. Hochmair, Mojca Unk, Jelena Spasic, Timur Cerić, Assia Konsoulova, Mircea Dediu, Krisztina Bogos, Alinta Hegmane, Kersti Oselin, Marko Stojiljkovic, Tina Roblek, Marko Jakopovic
BMC Proceedings.2024;[Epub]     CrossRef
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
Pınar Gursoy, Ali Murat Tatli, Dilek Erdem, Erdem Goker, Emir Celik, Nebi Serkan Demirci, Abdullah Sakin, Muhammed Mustafa Atci, Ertuğrul Bayram, Tuğba Akın Telli, Burak Bilgin, Ahmet Bilici, Baran Akangunduz, Sevinç Balli, Ahmet Demirkazik, Fatih Selçukb
Journal of Cancer Research and Clinical Oncology.2023; 149(2): 865.     CrossRef
Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison
Sai-Hong I. Ou, Huamao M. Lin, Jin-Liern Hong, Yu Yin, Shu Jin, Jianchang Lin, Minal Mehta, Pingkuan Zhang, Danny Nguyen, Joel W. Neal
Lung Cancer.2023; 179: 107186.     CrossRef
EGFR and ERBB2 exon 20 insertion/duplication in advanced non–small cell lung cancer: genomic profiling and clinicopathologic features
Ramakrishna R. Sompallae, Bilge Dundar, Natalya V. Guseva, Aaron D. Bossler, Deqin Ma
Frontiers in Oncology.2023;[Epub]     CrossRef
Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions
Ying-Ting Liao, Lei-Chi Wang, Ruei-Lin Sun, Yi-Chen Yeh, Hsu-Ching Huang, Chia-I Shen, Yen-Han Tseng, Tsu-Hui Hsiao, Heng-Sheng Chao, Yung-Hung Luo, Yuh-Min Chen, Chi-Lu Chiang
Journal of Cancer Research and Clinical Oncology.2023; 149(12): 10365.     CrossRef
EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies
Qianming Bai, Jialei Wang, Xiaoyan Zhou
Cancer Treatment Reviews.2023; 120: 102605.     CrossRef
A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments
Fenneke Zwierenga, Bianca A.M.H. van Veggel, Anke van den Berg, Harry J.M. Groen, Lili Zhang, Matthew R. Groves, K. Kok, E.F. Smit, T. Jeroen N. Hiltermann, Adrianus J. de Langen, Anthonie J. van der Wekken
Cancer Treatment Reviews.2023; 120: 102628.     CrossRef
Epidemiological characteristics and therapeutic advances of EGFR exon 20 insertion mutations in non‐small cell lung cancer
Binyang Pan, Jiaqi Liang, Haochun Shi, Kungeng Rao, Weigang Guo, Cheng Zhan
Thoracic Cancer.2023; 14(33): 3247.     CrossRef
Aumolertinib-based comprehensive treatment for an uncommon site of EGFR exon 20 insertion mutations with multiple metastases non-small cell lung cancer: a case report
Youjun Deng, Chenglin Yang, Wenyi Liu, Songhua Cai, Xiaotong Guo
Anti-Cancer Drugs.2022; 33(4): 406.     CrossRef
Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer
Neeraj Gupta, Philippe B. Pierrillas, Michael J. Hanley, Steven Zhang, Paul M. Diderichsen
CPT: Pharmacometrics & Systems Pharmacology.2022; 11(6): 731.     CrossRef
Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines
Timothée Olivier, Vinay Prasad
Translational Oncology.2022; 23: 101475.     CrossRef
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
Yasir Y. Elamin, Jacqulyne P. Robichaux, Brett W. Carter, Mehmet Altan, Hai Tran, Don L. Gibbons, Simon Heeke, Frank V. Fossella, Vincent K. Lam, Xiuning Le, Marcelo V. Negrao, Monique B. Nilsson, Anisha Patel, R.S.K. Vijayan, Jason B. Cross, Jianjun Zhan
Cancer Cell.2022; 40(7): 754.     CrossRef
EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors
Guangjian Yang, Yaning Yang, Jiaqi Hu, Haiyan Xu, Shuyang Zhang, Yan Wang
Frontiers in Pharmacology.2022;[Epub]     CrossRef
The mechanism of action of different generations of EGFR-inhibitors in malignant lung tumors. Literature review and data synthesis
Ainur F. Nasretdinov, Konstantin V. Menshikov, Alexander V. Sultanbaev, Shamil I. Musin, Nadezda I. Sultanbaeva, Irina A. Men'shikova
Journal of Modern Oncology.2022; 24(3): 340.     CrossRef
Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
Maria Garcia Campelo, Caicun Zhou, Suresh Ramalingam, Huamao Lin, Tae Kim, Gregory Riely, Tarek Mekhail, Danny Nguyen, Erin Goodman, Minal Mehta, Sanjay Popat, Pasi Jänne
Journal of Clinical Medicine.2022; 12(1): 112.     CrossRef
Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations
Guang-Jian Yang, Jun Li, Hai-Yan Xu, Yang Sun, Liu Liu, Hong-Shuai Li, Lu Yang, Yuan Zhang, Guo-Hui Li, Yan Wang
Lung Cancer.2021; 152: 39.     CrossRef
Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review
Heather Burnett, Helena Emich, Chris Carroll, Naomi Stapleton, Parthiv Mahadevia, Tracy Li, Rama Krishna Kancha
PLOS ONE.2021; 16(3): e0247620.     CrossRef
Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions
Noura J. Choudhury, Adam J. Schoenfeld, Jessica Flynn, Christina J. Falcon, Hira Rizvi, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Glenn Heller, Helena A. Yu, Marc Ladanyi, Gregory J. Riely
Clinical Cancer Research.2021; 27(10): 2920.     CrossRef
EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non–Small Cell Lung Cancer
Jose Luis Leal, Marliese Alexander, Malinda Itchins, Gavin M. Wright, Steven Kao, Brett G.M. Hughes, Nick Pavlakis, Stephen Clarke, Anthony J Gill, Hannah Ainsworth, Benjamin Solomon, Thomas John
Clinical Lung Cancer.2021; 22(6): e859.     CrossRef
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
Gregory J. Riely, Joel W. Neal, D. Ross Camidge, Alexander I. Spira, Zofia Piotrowska, Daniel B. Costa, Anne S. Tsao, Jyoti D. Patel, Shirish M. Gadgeel, Lyudmila Bazhenova, Viola W. Zhu, Howard L. West, Tarek Mekhail, Ryan D. Gentzler, Danny Nguyen, Sylv
Cancer Discovery.2021; 11(7): 1688.     CrossRef
Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions
Chie Morita, Tatsuya Yoshida, Masayuki Shirasawa, Ken Masuda, Yuji Matsumoto, Yuki Shinno, Shigehiro Yagishita, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Noriko Motoi, Yasushi Yatabe, Yuichiro Ohe
Scientific Reports.2021;[Epub]     CrossRef
EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy
Samy Chelabi, Xavier Mignard, Karen Leroy, Isabelle Monnet, Solenn Brosseau, Nathalie Theou-Anton, Marie-Ange Massiani, Sylvie Friard, Boris Duchemann, Elizabeth Fabre, Etienne Giroux-Leprieur, Jacques Cadranel, Marie Wislez
Cancers.2021; 13(20): 5132.     CrossRef
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer
Caicun Zhou, Suresh S. Ramalingam, Tae Min Kim, Sang-We Kim, James Chih-Hsin Yang, Gregory J. Riely, Tarek Mekhail, Danny Nguyen, Maria R. Garcia Campelo, Enriqueta Felip, Sylvie Vincent, Shu Jin, Celina Griffin, Veronica Bunn, Jianchang Lin, Huamao M. Li
JAMA Oncology.2021; 7(12): e214761.     CrossRef
A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes
Christos Chouaid, Thomas Filleron, Didier Debieuvre, Maurice Pérol, Nicolas Girard, Eric Dansin, Hervé Lena, Radj Gervais, Sophie Cousin, Josiane Otto, Roland Schott, David Planchard, Anne Madroszyk, Courèche Kaderbhai, Pascale DUBRAY-Longeras, Sandrine H
Targeted Oncology.2021; 16(6): 801.     CrossRef
External Quality Assurance of Current Technology for the Testing of Cancer-Associated Circulating Free DNA Variants
Sze Yee Chai, Rongxue Peng, Rui Zhang, Li Zhou, Nalishia Pillay, Kwang Hong Tay, Tony Badrick, Jinming Li, Martin P. Horan
Pathology & Oncology Research.2020; 26(3): 1595.     CrossRef
Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer
B. van Veggel, J.F. Vilacha Madeira R Santos, S.M.S. Hashemi, M.S. Paats, K. Monkhorst, D.A.M. Heideman, M. Groves, T. Radonic, E.F. Smit, E. Schuuring, A.J. van der Wekken, A.J. de Langen
Lung Cancer.2020; 141: 9.     CrossRef
EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study
Guangjian Yang, Jun Li, Haiyan Xu, Yaning Yang, Lu Yang, Fei Xu, Bing Xia, Viola W. Zhu, Misako Nagasaka, Yan Yang, Yapin Li, Weini Qiu, Jianming Ying, Sai-Hong Ignatius Ou, Yan Wang
Lung Cancer.2020; 145: 186.     CrossRef
Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors
YanRu Qin, Hong Jian, Xiaoling Tong, Xue Wu, Fufeng Wang, Yang W. Shao, Xinmin Zhao
Molecular Oncology.2020; 14(8): 1695.     CrossRef
The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
Shang-Gin Wu, Chong-Jen Yu, James Chih-Hsin Yang, Jin-Yuan Shih
Therapeutic Advances in Medical Oncology.2020; 12: 175883592094615.     CrossRef
Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: A study from India
Varsha Singh, Aruna Nambirajan, Prabhat Singh Malik, Sanjay Thulkar, Ravindra Mohan Pandey, Kalpana Luthra, Sudheer Arava, Ruma Ray, Anant Mohan, Deepali Jain
Lung Cancer.2020; 149: 53.     CrossRef
Effectiveness of Treatments for Advanced Non–Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations
Jenn-Yu Wu, Chong-Jen Yu, Jin-Yuan Shih
Clinical Lung Cancer.2019; 20(6): e620.     CrossRef
Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation
J. Chantharasamee, N. Poungvarin, P. Danchaivijitr, S. Techawatanawanna
BMC Cancer.2019;[Epub]     CrossRef
Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas
Ya Gao, Wies Vallentgoed, Pim French
Cancers.2018; 10(12): 489.     CrossRef